AX-2026-042185 · TB-500 · JEEP lot JEEP-2510-R9238

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.67	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.33	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — [D-Thr]-diastereomer	0.18	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	887.4964	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	887.4953	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-1.2	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	5.56	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.50	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.56	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.45	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White cake, partial shrinkage from vial wall	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.24	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	7.69	min	7.86 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.06	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	69,235	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Thr]-diastereomer	0.92	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 69,235, and skew follows the reported asymmetry factor of 1.06. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.18 % impurity against a 99.67 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	TB-500 — main peak	7.69	4,844,271	99.67	—
2	[D-Thr]-diastereomer	7.58	8,749	0.18	0.000
3	des-acetyl TB-500 (−42 Da)	7.17	3,888	0.08	-42.011
4	des-Gln truncate (−128 Da)	7.45	1,944	0.04	-128.059
5	C-terminal amide (−1 Da)	7.87	1,458	0.03	-0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 887.4964 Da, computed from C39H69N9O14. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 887.4953 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	444.7555	444.7549	-0.0006	56.4
1+	888.5037	888.5026	-0.0011	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.39	99.67	divergence -0.23 pp vs batch median
Total impurities (% area)	0.27	0.33
Largest single impurity (% area)	0.61	0.18
Water (%)	3.6	5.56
Counter-ion (%)	not stated	4.50
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	not stated	0.45
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 25 d) → laboratory (courier, dry ice, 6 d) → assay.
Assay date: 24 Jan 2026
Submitted to the index: 12 Feb 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 5

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

valley_drop12 Feb 2026

Largest single impurity is [D-Thr]-diastereomer at 0.18 % area, and it is the only named peak above 0.1 %. The integration is unambiguous and 99.67 % can be taken at face value.

des_gly12 Feb 2026

At 99.67 % the deletion-sequence family is at or below the reporting threshold. On a sequence with a hindered coupling that is a statement about coupling efficiency, and a good one.

baseline_noise12 Feb 2026

Baseline on this trace is flat enough that the reporting threshold is doing real work rather than hiding peaks in noise. That is a precondition for believing 99.67 % and it is not always met.

diode_array12 Feb 2026

Photodiode-array spectral homogeneity across the main peak would convert 99.67 % from a good number into a checked one. It is a free measurement on any instrument that already has the detector.

semax_met112 Feb 2026

Useful. Cross-referenced on my own copy.

Section 7

Related records

Same batch — lot JEEP-2510-R9238 n=12

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042186	JEEP-2510-R9238	Janoshik	2026-Q1	99.56	5.02	106.4	Buyer-sourced	2	MARGINAL
AX-2026-042187	JEEP-2510-R9238	Janoshik	2026-Q1	99.47	4.61	94.9	Buyer-sourced	2	MARGINAL
AX-2026-042188	JEEP-2510-R9238	VendorInvestigate	2026-Q1	99.38	4.97	92.7	Buyer-sourced	2	MARGINAL
AX-2026-042189	JEEP-2510-R9238	Janoshik	2026-Q1	99.93	4.88	95.1	Buyer-sourced	2	MARGINAL
AX-2026-042190	JEEP-2510-R9238	PeptideMeter	2026-Q1	99.89	4.52	—	Buyer-sourced	2	MARGINAL
AX-2026-042191	JEEP-2510-R9238	Janoshik	2026-Q1	99.69	4.99	106.9	Buyer-sourced	2	MARGINAL
AX-2026-042192	JEEP-2510-R9238	Medutest	2026-Q1	99.93	4.59	106.4	Buyer-sourced	3	FAIL
AX-2026-042193	JEEP-2510-R9238	VendorInvestigate	2026-Q1	99.52	4.54	—	Buyer-sourced	2	MARGINAL
AX-2026-042194	JEEP-2510-R9238	PeptideMeter	2026-Q1	99.42	4.88	91.9	Buyer-sourced	2	MARGINAL
AX-2026-042195	JEEP-2510-R9238	Janoshik	2026-Q1	99.44	5.25	—	Buyer-sourced	2	MARGINAL
AX-2026-042196	JEEP-2510-R9238	Janoshik	2026-Q1	99.93	4.60	107.0	Laboratory-retained	2	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent TB-500 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041776	ASY	ASY-{CAT}-2167	Janoshik	2026-Q3	99.92	4.61	98.2	Buyer-sourced	0	PASS
AX-2026-041777	ASY	ASY-{CAT}-2167	PeptideMeter	2026-Q3	99.78	4.09	92.8	Buyer-sourced	0	PASS
AX-2026-041782	ASY	ASY-{CAT}-2167	Nordanalyt	2026-Q3	99.93	3.94	—	Buyer-sourced	0	PASS
AX-2026-041774	ASY	ASY-{CAT}-2167	PeptideMeter	2026-Q3	99.93	4.41	96.2	Buyer-sourced	0	PASS
AX-2026-042127	JEEP	JEEP-2602-V8614	Medutest	2026-Q3	99.68	3.55	—	Buyer-sourced	1	FAIL
AX-2026-042021	AMB	AMB-2602-P5987	VendorInvestigate	2026-Q3	99.86	4.79	101.4	Buyer-sourced	0	PASS
AX-2026-041780	ASY	ASY-{CAT}-2167	Janoshik	2026-Q3	99.93	3.48	102.5	Buyer-sourced	1	FAIL
AX-2026-041779	ASY	ASY-{CAT}-2167	Janoshik	2026-Q3	99.84	3.85	—	Buyer-sourced	1	FAIL

Other recent JEEP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042177	Hexarelin	JEEP-2608-Y9547	Janoshik	2026-Q3	99.90	3.42	—	Buyer-sourced	0	PASS
AX-2026-042162	Semaglutide	JEEP-2607-X9091	Janoshik	2026-Q3	98.98	3.46	—	Laboratory-retained	1	MARGINAL
AX-2026-042127	TB-500	JEEP-2602-V8614	Medutest	2026-Q3	99.68	3.55	—	Buyer-sourced	1	FAIL
AX-2026-042123	TB-500	JEEP-2602-V8614	PeptideMeter	2026-Q3	99.93	3.80	—	Buyer-sourced	0	PASS
AX-2026-042124	TB-500	JEEP-2602-V8614	PeptideMeter	2026-Q3	99.91	3.37	104.9	Buyer-sourced	0	PASS
AX-2026-042178	Hexarelin	JEEP-2608-Y9547	VendorInvestigate	2026-Q3	99.68	4.03	—	Buyer-sourced	0	PASS
AX-2026-042163	Semaglutide	JEEP-2607-X9091	Nordanalyt	2026-Q3	99.46	4.52	—	Buyer-sourced	1	MARGINAL
AX-2026-042122	TB-500	JEEP-2602-V8614	PeptideMeter	2026-Q3	99.60	3.58	97.0	Buyer-sourced	0	PASS